Industrial Catalytic Production Process of Erythromycin
-
Published:2024-07-21
Issue:7
Volume:12
Page:1533
-
ISSN:2227-9717
-
Container-title:Processes
-
language:en
-
Short-container-title:Processes
Author:
Adamantidi Theodora1, Panoutsopoulou Ellie1, Stavrakoudi Evangelia1, Tzevelekou Panagiota1, Kokkinos Nikolaos C.12ORCID
Affiliation:
1. School of Chemistry, Faculty of Sciences, Democritus University of Thrace, Ag. Loukas, 654 04 Kavala, Greece 2. Hephaestus Laboratory, Faculty of Sciences, Democritus University of Thrace, Ag. Loukas, 654 04 Kavala, Greece
Abstract
The impact of COVID-19’s unexpected outbreak forced the scientific community to seek alternative treatment methods in order to overcome the hindrance of traditional medicine in terms of alleviating the symptoms of this virus. Erythromycin, which was introduced in 1952, is an antibiotic that is reported to pose as an effective substitute medication for various ailments such as skin, respiratory, bone, and female reproductive conditions, and cancer, as well as the newly added COVID-19. The importance of both the erythromycin molecule and the catalyst of its production, namely P450eryF of the cytochrome P450 family, in many health-concerned and environmentally related applications, has led several countries, the World Health Organization (WHO) and the health industry to recruit and cooperate with numerous universities and institutions, in an attempt to tackle the demand for efficient antibiotics. The aim of this study is to discuss and further analyze the overall structure and catalytic mechanism of erythromycin’s synthesis and industrial production, in order to gain a better comprehension of this molecule’s significance and value in the pharmaceutical field. This was carried out through the citation of the current production rates per country and the latest statistics and published patents. As implied in this manuscript, the demand for an increase and improvement in the production of erythromycin and its antibiotic derivatives should be globally promoted to deliver more effective results against infectious diseases, such as COVID-19.
Reference76 articles.
1. Cytochrome P450 Enzymes;Guengerich;Am. Sci.,1993 2. Recollection of the Early Years of the Research on Cytochrome P450;OMURA;Proc. Jpn. Acad. Ser. B Phys. Biol. Sci.,2011 3. Robertsen, H.L., and Musiol-Kroll, E.M. (2019). Actinomycete-Derived Polyketides as a Source of Antibiotics and Lead Structures for the Development of New Antimicrobial Drugs. Antibiotics, 8. 4. Grela, A., Kuc, J., Klimek, A., Matusik, J., Pamuła, J., Franus, W., Urbański, K., and Bajda, T. (2023). Erythromycin Scavenging from Aqueous Solutions by Zeolitic Materials Derived from Fly Ash. Molecules, 28. 5. Farzam, K., Nessel, T.A., and Quick, J. (2023). Erythromycin. StatPearls, StatPearls Publishing.
|
|